Global Oil,Gas and Pharmaceutical Business Confidence Market Research Report q4 2013 Available on Researchmoz.us

Researchmoz presents this most up-to-date research on"Global Oil,Gas and Pharmaceutical Business Confidence Market Research Report q4 2013 Available on Researchmoz.us".The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Remote Patient Monitoring Market.

Global Oil and Gas Business Confidence Report Q4 2013 http://www.researchmoz.us/global-oil-and-gas-business-confidence-report-q4-2013-report.html

“Oil and Gas Business Confidence Report Q4 2013” is a new report by Kable that analyzes the industry sentiments, globally, on the latest economic and consumer issues and their impact upon investment decisions and growth prospects within the oil and gas industry. This report also examines the executive opinion about the current and future state of the economy and its retrospective affect on the industry. Furthermore, it analyzes the likely effect of supplier price changes, sales performance, and staff headcount within the industry over the next six months. In addition, it provides an overview of the key priorities, threats, and opportunities for the global oil and gas industry over the next six months.

Introduction and Landscape

Why was the report written?

This report is the result of an extensive survey drawn from Kable's exclusive panel of leading global oil and gas industry executives. The report analyzes current economic conditions prevailing across the globe and their impact on the oil and gas industry, and forecasts company and industry growth prospects over the next six months. Furthermore, it also provides information about the impact of consumer confidence, supplier prices, and staff headcount likely to affect the investment decisions of the industry over the next six months.

What is the current market landscape and what is changing?

Overall, 73% and 63% of respondents expressed positive outlook for both company and industry growth prospects, respectively, over the next six months.

What are the key drivers behind recent market changes?

'Increasing sales', 'improving operational efficiency', and 'customer retention' are the most preferred priorities by industry executives operating globally.

What makes this report unique and essential to read?

“Oil and Gas Business Confidence Report Q4 2013” is a new report by Kable that analyzes the industry sentiments, globally, on the latest economic and consumer issues and their impact upon investment decisions and growth prospects within the oil and gas industry. This report also examines the executive opinion about the current and future state of the economy and its retrospective affect on the industry. Furthermore, it analyzes the likely effect of supplier price changes, sales performance, and staff headcount within the industry over the next six months. In addition, it provides an overview of the key priorities, threats, and opportunities for the global oil and gas industry over the next six months.

 

Pharmaceutical Business Confidence Report Q4 2013 http://www.researchmoz.us/pharmaceutical-business-confidence-report-q4-2013-report.html

“Pharmaceutical Business Confidence Report Q4 2013” is a new report by Kable that analyzes pharmaceutical industry executives' views on the global economy, expectations on consumer confidence, supplier prices, key business concerns, and how executives' future investments are set to change in Q4 2013. This report also gives you access to regional analysis of industry outlook, industry and company growth prospects, future opportunities, staff hiring, and sales performance. Apart from providing access to the opinions and strategies of global pharmaceutical industry executives, it also examines their actions surrounding business priorities, threats and opportunities, and future investment areas over the next six months.

Introduction and Landscape

Why was the report written?

This report is the result of an extensive survey drawn from Kable's exclusive panel of leading global pharmaceutical industry executives. The report analyzes current economic conditions prevailing across the globe and their impact on the pharmaceutical industry, and forecasts company and industry growth prospects over the next six months. Furthermore, it also provides information about the impact of consumer confidence, supplier prices, and staff headcount likely to affect the investment decisions of the industry over the next six months.

What is the current market landscape and what is changing?

Overall, 66% and 50% of global pharmaceutical industry executives are optimistic about the future growth prospects of both their company and the industry over the next six months, respectively.

What are the key drivers behind recent market changes?

Optimism towards industry and company growth is driven by the improving global economic conditions, increasing in consumer spending, and the introduction of new products in the market.

 

For More Information Kindly Contact:
Email: sales@researchmoz.us
WebSite: http://www.researchmoz.us/
Blog: http://globalandchinamarket.blogspot.com
http://deepmarketresearchreports.blogspot.com/

Indian Wine Market Forecast to 2018

Indian Wine Market has been showing a steady growth. The demand of both the domestic and foreign wines has been growing day by day. There is enough room for each and every wine brand, be it Indian or foreign, in the Indian market as the market has registered a significant percentage of growth in both volume and value terms in recent years.

The strong economic growth of the last few years and increasing wine culture among the new wealthy Indian middle class combined with a greater exposure to western lifestyle has created hunger for different categories of wines.

In order to help manufacturers and exporters to better understand the Indian wine market, IBNA Research, a division of Indian Business News Agency (IBNA), has launched a new market research report titled “Indian Wine Market Forecast to 2018”.

Indian Wine Market Forecast to 2018 is a comprehensive research that contains detail statistics, in-depth analysis, and quality research on Indian wine market. This report is unique in its collection of highly relevant data, from legislation and imports to pricing levels, analyses of market share, market growth and more.

The report starts with an introduction of India's demographic and macro-economic indicators, including focus on Indian Cities for Growth.

 

For More Information Visit: http://www.researchmoz.us/indian-wine-market-forecast-to-2018-report.html

Department Of Pharmaceuticals Has Prepared A Pharma Vision 2020

The Department of Pharmaceuticals has prepared a 'Pharma Vision 2020' document for making India one of the leading destinations for end-to-end drug discovery and innovation. The department provides requisite support by way of world class infrastructure, internationally competitive scientific manpower for pharma research and development (R&D), venture fund for research in the public and private domain and such other measures.

Sector Structure/ Market Size

The domestic pharma market has reported total sales of Rs 6,370 crore (US$ 1.03 billion) in the month of May 2013, registering a growth of 6.8 per cent, as per IMS Health. The major factors responsible are increasing sales of generic medicines, continued growth in chronic therapies and a greater penetration in rural markets.The cumulative drugs and pharmaceuticals sector has attracted foreign direct investments (FDI) worth US$ 11,304.91 million during April 2000 to April 2013, according to the latest data published by Department of Industrial Policy and Promotion (DIPP).

Growth

The Indian pharmaceutical industry would continue to experience strong growth as structural growth drivers continue to remain impervious. The industry is expected to revert a growth of 10-12 percent in 2013-14, according to a study by ICRA. It is also expected that in-organic investments will gain momentum in the medium-term as companies plan to create stronger presence in emerging markets and build expertise in select therapy areas. Among the top 10 companies, Cipla with total sales of Rs 302 crore (US$ 49.13 million), Sun Rs 297 crore (US$ 48.32 miliion), Alkem Rs 222 crore (US$ 36.12 million) and Sanofi Rs 186 crore (US$ 30.26 million) were the fastest growing corporations for the month of May 2013.

Exports

Pharmaceutical exports from the country during 2012-13 stood at US$14.6 billion, up from US$13.2 billion the previous year, as per P V Appaji, Director General, Pharmexcil.The Ministry of Commerce has targeted Indian pharma sector exports at US$ 25 billion by 2016. The Government has also planned a ‘Pharma India’ brand promotion action plan spanning over a three-year period to give an impetus to generic exports. In order to boost the export capability, Export-Import Bank of India (Exim Bank), has decided to expand the scope of its finance to pharmaceutical companies for extended repayment periods. Eligible export oriented companies can avail finance from Exim Bank for a maximum repayment period of 10 years with a moratorium of up to 36 months. “Of the export markets, Indian pharma will focus on the US market which presents significant opportunities for the next two years for generics, due to patent cliffs and recent changes in healthcare policies,” said the India Ratings report on outlook for Indian pharmaceuticals for 2013.

Generics

Generics will continue to dominate the market while patent-protected products are likely to constitute 10 per cent of the pie till 2015, according to McKinsey report 'India Pharma 2015- Unlocking the potential of Indian Pharmaceuticals market'. Global demand for generic drugs from Indian companies is booming as developed nations battle rising healthcare costs. As a result, generics companies are increasingly focusing on expanding presence in relatively under-penetrated markets (i.e. France, Spain & Italy), branded generic markets of East Europe and niche areas like complex generics, OTCs etc.

Source: http://www.ibef.org/industry/pharmaceutical-india.aspx

Good News For The Indian Pharmaceuticals Industry

The issue was raised to help the Indian domestic pharmaceutical industry raise its share in the Japanese market, as part of the FTA (Free Trade Agreement) signed between both the nations. India currently holds less than one per cent share of the Japanese pharmaceutical market. 

The lifting of import duties would help both the nations realize true benefits of CEPA (Comprehensive Economic Partnership Agreement) signed on August 1, 2011. It is believed that CEPA will help raise the bilateral trade between both the nations considerably up to USD 25 billion by year 2014. The insistence of Anand Sharma to remove all non-tariff barriers is seen as a win-win situation for both the economies. The Indian capability to provide generic drug based medicines for meeting the increasing demand across the Japanese market will help Indian companies to boost their market share in the world’s second largest pharmaceutical market, and provide Japan with cheaper and quality generic medicines.

As part of the agreement, Indian pharmaceutical exporting companies will be treated at par with domestic Japanese pharmaceutical companies, while considering their applications for drug registration. The move is seen as a great sentiment booster across the Indian pharmaceutical companies, who till now were facing trade barriers to expand their Japanese market presence. The prominent non-tariff barriers included language and prolonged and tiring registration processes.

The meet also saw both parties discussing the requirement to quickly start negotiations for nursing and healthcare services to further boost bilateral ties. Ever since CEPA came into enforcement, the trade between both nations has reached USD 18.3 billion in the year 2011 - 2012, a USD 4.5 billion rise from that in the last financial year (2010 – 2011).